New FDA-Approved Treg Therapy to Reduce Chronic GVHD After Allogeneic HSCT
In brief
Engineered donor graft reduces chronic GVHD and non-relapse mortality
In the randomized, multicenter phase 3 Precision-T trial, a centrally manufactured, defined donor graft reduced moderate-to-severe chronic graft-versus-host disease and non-relapse mortality, without loss of graft-versus-leukemia activity or increased graft failure and infection. The abstract gives no effect sizes, leaving the magnitude of benefit unclear; the proposed immune-regulating mechanism also needs further study.
- Journal
- Blood (Q1)
- Published
- 2 October 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Nelson J Chao
- PMID
- 42826158
- DOI
- 10.1182/blood.2026035591
Why clinicians should know about it
- Picked for Hematology (paper of the day, 4 October 2026): Phase 3 trial of FDA‑approved Treg therapy for chronic GVHD
Abstract
The Precision-T phase 3 trial is the first randomized, multicenter demonstration that a centrally manufactured defined allograft is effective markedly reducing moderate-to-severe chronic GVHD and non-relapse mortality without loss of graft versus leukemia or graft failure and infection. The engineered graft appears to instruct immune reconstitution toward a regulated, tolerance-associated state, giving the product a mechanism for further studies. The question is how far we can further program it.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.